It is generally accepted that hypoxia in tumors often causes resistance to anti-tumor drugs through the HIF-1 cascade; therefore, the inhibition of CA-IX, closely associated with hypoxia, can enhance the effect of anti-tumor drugs, leading to a decrease in the dose of anti-tumor drugs for therapy, which may help realize safer cancer treatments. This evidence concerns the gene CA9 and neoplasm.